Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

Overview

About this study

The purpose of this study is to determine the effect of endogenous GLP-1 secretion on islet function in people with Typr 2 Diabetes Mellitus (T2DM).

GLP-1 is a hormone made by the body that promotes the production of insulin in response to eating. However, there is increasing evidence that this hormone might help support the body’s ability to produce insulin when diabetes develops. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria – Non-diabetic Subjects:

  • Weight-stable, non-diabetic subjects using the methods described above.

Exclusion Criteria - Non-diabetic Subjects: 

  • Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • HbA1c ≥ 6.5%
  • Use of glucose-lowering agents.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Subsequently, subjects will then undergo an Oral Glucose Tolerance Test to ensure that they have a fasting glucose ≤ 125mg/dl and a two-hour glucose ≤ 200mg/dl.

Inclusion Criteria – Diabetic Subjects:

  • Weight-stable, diabetic subjects treated with diet and lifestyle alone or with metformin monotherapy using the methods described above. 

Exclusion Criteria - Diabetic Subjects:

  • Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • Use of any glucose-lowering agent other than metformin.
  • 2 or more fasting glucose values > 250mg/dl on medication or after medication withdrawal.
  • Unwillingness or inability to withdraw medication for three weeks prior to, and for the duration of the study.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • The two groups will be matched for age, sex and weight.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Open for enrollment

Contact information:

Adrian Vella M.D.

(507) 284-1920

vella.adrian@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20520180

Mayo Clinic Footer